Michael Barbella, Managing Editor11.04.22
HeartBeam Inc. is expanding its product portfolio to better serve the cardiac wearable technology market. The product pipeline advancement adds arrhythmia detection capabilities to address the multibillion-dollar global market for atrial fibrillation and other arrhythmia monitoring.
Building on HeartBeam’s recently issued patents, the broader product portfolio enables the following:
To overcome potential supply chain issues, procurement of critical components for the company’s planned AIMIGo device production quantities for 2023 are in progress.
“We are pleased to announce that our AIMIGo heart attack solution will be significantly enhanced by the addition of automated atrial fibrillation detection and smartwatch connectivity,” HeartBeam Chief Business Officer Jon Hunt, Ph.D., said. “This is an immense step forward for our AIMIGo platform as it adds a significant and established market for detection of atrial arrhythmias.”
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the FDA.
Building on HeartBeam’s recently issued patents, the broader product portfolio enables the following:
- Introducing a 3-lead 3D vector electrocardiogram (VECG) credit card-sized device, the HeartBeam AIMIGo 3L, that records the X,Y,Z cardiac activity and displays the signals for clinician review, providing the regulatory foundation for subsequent products in HeartBeam’s product portfolio. The 510(K) submission to the United States Food and Drug Administration (FDA) is planned for this quarter.
- Leveraging recently issued patents to incorporate both synthesized baseline and symptomatic 12-lead signals for enhanced diagnostic accuracy as well as the addition of atrial fibrillation detection capability in the AIMIGo 12L device for FDA 510(K) submission in Q2 2023.
- Broadening of the product portfolio profile to enable smartwatch connectivity to HeartBeam’s platform in future products as an optional monitoring solution for the clinician and the patient.
To overcome potential supply chain issues, procurement of critical components for the company’s planned AIMIGo device production quantities for 2023 are in progress.
“We are pleased to announce that our AIMIGo heart attack solution will be significantly enhanced by the addition of automated atrial fibrillation detection and smartwatch connectivity,” HeartBeam Chief Business Officer Jon Hunt, Ph.D., said. “This is an immense step forward for our AIMIGo platform as it adds a significant and established market for detection of atrial arrhythmias.”
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the FDA.